Related references
Note: Only part of the references are listed.Current treatment options and investigational drugs for Waldenstrom's Macroglobulinemia
Maria Gavriatopoulou et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2017)
Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies
Andrew Aw et al.
DRUGS & AGING (2017)
A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies
Harriet S. Walter et al.
BLOOD (2016)
Discovery of highly potent and selective Bruton's tyrosine kinase inhibitors: Pyridazinone analogs with improved metabolic stability
Wendy B. Young et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2016)
Discovery and Structural Optimization of N5-Substituted 6,7-Dioxo-6,7-dihydropteridines as Potent and Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors against L858R/T790M Resistance Mutation
Yongjia Hao et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia
Jennifer R. Brown et al.
BLOOD (2015)
KLIFS: A Knowledge-Based Structural Database To Navigate Kinase-Ligand Interaction Space
Oscar P. J. van Linden et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Bruton's Tyrosine Kinase (BTK) Inhibitors in Clinical Trials
Jan A. Burger
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2014)
A review of a novel, Bruton’s tyrosine kinase inhibitor, ibrutinib
Chung-Shien Lee et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2014)
Ibrutinib and novel BTK inhibitors in clinical development
Akintunde Akinleye et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2013)
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Bruton Tyrosine Kinase (BTK) and Its Role in B-cell Malignancy
Joseph J. Buggy et al.
INTERNATIONAL REVIEWS OF IMMUNOLOGY (2012)
Meeting the Decision-Making Preferences of Patients With Breast Cancer in Oncology Consultations: Impact on Decision-Related Outcomes
Richard Brown et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis
Julie A. Di Paolo et al.
NATURE CHEMICAL BIOLOGY (2011)
The Src, Syk, and Tec family kinases: Distinct types of molecular switches
J. Michael Bradshaw
CELLULAR SIGNALLING (2010)
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
Lee A. Honigberg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain
Abdalla J. Mohamed et al.
IMMUNOLOGICAL REVIEWS (2009)
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
Wenjun Zhou et al.
NATURE (2009)
Structure and chemical inhibition of the RET tyrosine kinase domain
Phillip P. Knowles et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy
RA Friesner et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
BCR targets cyclin D2 via Btk and the p85α subunit of PI3-K to induce cell cycle progression in primary mouse B cells
J Glassford et al.
ONCOGENE (2003)
Defective expression of Bruton's tyrosine kinase in acute lymphoblastic leukemia
PA Goodman et al.
LEUKEMIA & LYMPHOMA (2003)
Phosphorylation of Bruton's tyrosine kinase by c-Abl
CM Bäckesjö et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2002)
The Tec family of cytoplasmic tyrosine kinases: mammalian Btk, Bmx, Itk, Tec, Txk and homologs in other species
CIE Smith et al.
BIOESSAYS (2001)
Phospholipase C-γ2 couples Bruton's tyrosine kinase to the NF-κB signaling pathway in B lymphocytes
JB Petro et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Bruton's tyrosine kinase links the B cell receptor to nuclear factor κB activation
UD Bajpai et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
Share Paper
